Robert J. Bechard
Corporate Officer/Principal chez Intelgenx Corp.
Profil
Robert J.
Bechard is currently the Vice President-Corporate Development at Intelgenx Corp.
He previously worked as a Director at Angiogenix, Inc., Conforma Therapeutics Corp., Cognetix, Inc., and Viron Therapeutics, Inc. He was also a Senior Member at RBC Life Sciences, Inc. and the Managing Partner at RBC Capital Partners Ltd.
Additionally, he served as the Executive VP-Corporate Development & Licensing at Tetra Bio-Pharma, Inc. from 2018 to 2020 and as the Chief Business Officer at Aronnax International, Inc. from 2014 to 2016.
Bechard holds an MBA from Concordia University, an undergraduate degree from the University of New Brunswick, and a graduate degree from the London School of Economics & Political Science.
Postes actifs de Robert J. Bechard
| Sociétés | Poste | Début |
|---|---|---|
Intelgenx Corp.
 Intelgenx Corp. Pharmaceuticals: MajorHealth Technology Intelgenx Corp. develops oral-controlled release pharmaceutical products. The firm offers pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. The company was founded in 2003 and is headquartered in Saint-Laurent, Canada. | Corporate Officer/Principal | 18/01/2016 |
Anciens postes connus de Robert J. Bechard
| Sociétés | Poste | Fin |
|---|---|---|
| TETRA BIO-PHARMA INC. | Corporate Officer/Principal | 01/05/2020 |
Aronnax International, Inc.
 Aronnax International, Inc. BiotechnologyHealth Technology Aronnax International, Inc. provides pre-clinical drug discovery and development services. The company was founded in 2005 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/01/2016 |
RBC Capital Partners Ltd.
 RBC Capital Partners Ltd. Investment ManagersFinance RBC Capital Partners Ltd. is a Venture Capital firm, a subsidiary of RBC Dominion Securities, Inc. founded in 1900. RBC Capital Partners Ltd. is headquartered in Toronto, Canada with offices across the globe. | Private Equity Investor | 01/02/2009 |
Foragen Technologies Management, Inc.
 Foragen Technologies Management, Inc. Investment ManagersFinance Foragen Technologies Management, Inc. is a venture capital firm located in Saskatoon, Saskatchewan | Corporate Officer/Principal | 01/11/2008 |
Angiogenix, Inc.
 Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA | Directeur/Membre du Conseil | 06/03/2008 |
Formation de Robert J. Bechard
| Concordia University | Masters Business Admin |
| University of New Brunswick | Undergraduate Degree |
| London School of Economics & Political Science | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| RBC LIFE SCIENCES, INC. | Health Technology |
| TETRA BIO-PHARMA INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Angiogenix, Inc.
Angiogenix, Inc. Pharmaceuticals: MajorHealth Technology Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA | Health Technology |
Conforma Therapeutics Corp.
 Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Health Technology |
RBC Capital Partners Ltd.
RBC Capital Partners Ltd. Investment ManagersFinance RBC Capital Partners Ltd. is a Venture Capital firm, a subsidiary of RBC Dominion Securities, Inc. founded in 1900. RBC Capital Partners Ltd. is headquartered in Toronto, Canada with offices across the globe. | Finance |
Cognetix, Inc.
 Cognetix, Inc. Drugstore ChainsRetail Trade Cognetix, Inc. discovered and developed drugs. Its products were used for the treatment of epilepsy, local anesthesia, heart disease, stroke, neuromuscular back pain, multiple sclerosis, and spinal cord injury. The company was founded in 1996 by Dennis B. Farrar, Baldomero M. Olivera and J. Michael McIntosh and was headquartered in Salt Lake City, UT | Retail Trade |
Foragen Technologies Management, Inc.
Foragen Technologies Management, Inc. Investment ManagersFinance Foragen Technologies Management, Inc. is a venture capital firm located in Saskatoon, Saskatchewan | Finance |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Intelgenx Corp.
Intelgenx Corp. Pharmaceuticals: MajorHealth Technology Intelgenx Corp. develops oral-controlled release pharmaceutical products. The firm offers pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. The company was founded in 2003 and is headquartered in Saint-Laurent, Canada. | Health Technology |
Aronnax International, Inc.
Aronnax International, Inc. BiotechnologyHealth Technology Aronnax International, Inc. provides pre-clinical drug discovery and development services. The company was founded in 2005 and is headquartered in Montreal, Canada. | Health Technology |